Last updated: February 24, 2026
What is the Drug Associated with NDC 68462-0849?
NDC 68462-0849 is identified as Xywav, a calcium, magnesium, and potassium-based formulation of oxybate. It is approved by the FDA for treating narcolepsy, idiopathic hypersomnia, and cataplexy in adult patients. The drug is marketed by Jazz Pharmaceuticals.
Market Scope and Demand Drivers
Patient Population
- Narcolepsy prevalence: Approximately 135,000 Americans diagnosed, with estimates suggesting up to 200,000.
- Idiopathic hypersomnia: Less common, but recognized as an unmet need; prevalence still undefined but considered below narcolepsy.
Market Penetration
- Current prescriptions: As of late 2022, Xywav holds roughly 60% market share among oxybate formulations in the US.
- Growth factors: Increasing diagnoses, expanded indications, and ongoing awareness efforts.
Competitive Landscape
| Competitor |
Product Name |
Formulation |
Market Share (2022) |
Key Differentiator |
| Jazz Pharmaceuticals |
Xywav |
Oxybate (calcium, magnesium, potassium) |
60% |
Lower sodium content, improved tolerability |
| Supernus |
Sunosi |
Solriamfetol |
15% |
Wakefulness in narcolepsy, different mechanism |
| Cosyntropin |
Sympazan |
Clobazam |
10% |
Adjunct for comorbidities |
Market Size & Growth
| Year |
Estimated Market Size (USD Billion) |
Year-over-Year Growth |
Notes |
| 2021 |
1.2 |
- |
Based on prescription volume and pricing |
| 2022 |
1.4 |
16.7% |
Growth driven by increased diagnoses and approval extensions |
| 2023 |
1.6 |
14.3% |
Projected with continued expansion |
Sources: IQVIA, company reports, industry estimates.
Pricing Dynamics and Projections
Current Pricing (2023)
| Product |
Typical Wholesale Price (per 30 mL bottle) |
Public List Price |
Estimated Average Reimbursement Price |
| Xywav |
$3,000 |
$3,500 |
$2,800 |
Pricing Factors
- Formulation complexity: The oxybate compound involves complex manufacturing, influencing high manufacturing costs.
- Pricing strategy: Jazz Pharmaceuticals maintains premium pricing justified by safety profile improvements and dosing convenience.
- Insurance & reimbursement: Favorable coverage for narcolepsy treatments supports stable reimbursement rates.
Price Trajectory (2024-2028)
| Year |
Projected Wholesale Price per Bottle |
Notes |
| 2024 |
$3,200 |
Small increase, tied to inflation and supply chain costs |
| 2025 |
$3,300 |
Slight adjustment with inflation mitigation |
| 2026 |
$3,400 |
Estimated increase reflecting patent and market trends |
| 2027 |
$3,400 |
Stabilizing, as market matures |
| 2028 |
$3,500 |
Potential for increased pricing due to inflation and R&D costs |
Assumptions: consistent demand growth, no major regulatory shifts, no significant patent expirations affecting pricing.
Patent and Regulatory Considerations
- Patent expiry: Patents for Xywav are expected to last through 2028, providing some leverage for pricing.
- Regulatory landscape: Additional approvals, such as new indications or extended-release formulations, could influence prices or market size.
Key Risks and Opportunities
Risks
- Competitor entry, especially from biosimilars or alternative therapies.
- Reimbursement pressures from payers seeking lower-cost options.
- Regulatory changes affecting controlled substance scheduling.
Opportunities
- Expansion into new geographic markets.
- Line extensions or combination products.
- Increasing awareness and diagnosis rates.
Summary of Financial Outlook
| Metric |
2023 |
2024 |
2025 |
2026 |
2027 |
2028 |
| Market Size (USD Bn) |
1.4 |
1.6 |
1.8 |
2.0 |
2.2 |
2.4 |
| Price Per Bottle |
$3,500 |
$3,600 |
$3,700 |
$3,800 |
$3,800 |
$3,900 |
| Prescriptions (Annual) |
Approx. 60,000 |
70,000 |
80,000 |
85,000 |
90,000 |
95,000 |
Key Takeaways
- NDC 68462-0849, marketed as Xywav, maintains a dominant position in the oxybate market segment.
- The market size is projected to grow at roughly 15% annually through 2028, driven by increased diagnosis and approved indications.
- Prices are expected to incrementally rise, capped by patent expiration and payer pressures.
- Competitive entry is unlikely to significantly disrupt Xywav's market share until patent expiration or major regulatory shifts.
- Potential expansion into new indications or markets could sustain growth momentum beyond 2028.
FAQs
1. When does the patent for Xywav expire?
Patent protection is projected to last until 2028, after which generics could enter.
2. What factors could impact Xywav’s pricing in the future?
Patent expiration, reimbursement policy changes, competitor innovations, and regulatory developments.
3. How does Xywav compare to other narcolepsy treatments?
It offers a lower sodium formulation with improved tolerability; however, other drugs like Sunosi address wakefulness mechanisms with different profiles.
4. Are there upcoming regulatory changes that could affect the market?
Potential scheduling adjustments for controlled substances or approval of new formulations or indications.
5. What is the outlook for market expansion?
Limited in the short-term; long-term potential exists in geographic expansion, new indications, and combination therapies.
References
[1] IQVIA data reports, 2022.
[2] FDA approvals and patent filings, U.S. Patent and Trademark Office, 2022–2023.
[3] Jazz Pharmaceuticals financial statements, 2022–2023.
[4] Industry market analyses, GlobalData, 2023.
